The stock of Adc Therapeutics SA (NYSE: ADCT) has decreased by -8.44 when compared to last closing price of 3.20. Despite this, the company has experienced a 3.90% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-07 that ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.
Is It Worth Investing in Adc Therapeutics SA (NYSE: ADCT) Right Now?
The stock has a 36-month beta value of 1.63. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADCT is 79.21M, and at present, short sellers hold a 4.43% of that float. On November 08, 2024, the average trading volume of ADCT was 356.93K shares.
ADCT’s Market Performance
The stock of Adc Therapeutics SA (ADCT) has seen a 3.90% increase in the past week, with a 2.09% rise in the past month, and a 10.15% gain in the past quarter. The volatility ratio for the week is 8.09%, and the volatility levels for the past 30 days are at 6.61% for ADCT. The simple moving average for the last 20 days is -3.54% for ADCT stock, with a simple moving average of -19.89% for the last 200 days.
Analysts’ Opinion of ADCT
Guggenheim, on the other hand, stated in their research note that they expect to see ADCT reach a price target of $11. The rating they have provided for ADCT stocks is “Buy” according to the report published on March 28th, 2024.
ADCT Trading at -2.97% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.49% of loss for the given period.
Volatility was left at 6.61%, however, over the last 30 days, the volatility rate increased by 8.09%, as shares surge +6.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, ADCT rose by +3.90%, which changed the moving average for the period of 200-days by +39.52% in comparison to the 20-day moving average, which settled at $3.04. In addition, Adc Therapeutics SA saw 76.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADCT starting from Redmile Group, LLC, who purchase 400,000 shares at the price of $2.81 back on Jul 01 ’24. After this action, Redmile Group, LLC now owns 15,669,217 shares of Adc Therapeutics SA, valued at $1,124,000 using the latest closing price.
Redmile Group, LLC, the 10% Owner of Adc Therapeutics SA, purchase 400,000 shares at $2.81 during a trade that took place back on Jul 01 ’24, which means that Redmile Group, LLC is holding 12,995,040 shares at $1,124,000 based on the most recent closing price.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -2.1 for the present operating margin
- 0.9 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.24. The total capital return value is set at -0.45. Equity return is now at value -705.53, with -49.14 for asset returns.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated -6.94 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at -0.87. The interest coverage ratio of the stock is -2.74.
Currently, EBITDA for the company is -145.78 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 1.61. The receivables turnover for the company is 2.92for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
To sum up, Adc Therapeutics SA (ADCT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
